The new guide from the European LeukemiaNet (ELN) for AML risk stratification and recent studies [4,7,8,9,10] have established that patients with a combination of mutated NPM1 without FLT3/ITD had to be considered of favorable risk. The gene discussed is FLT3; the disease is acute myeloid leukemia.